ProCE Banner Activity

Advances to Improve Clinical Outcomes and Quality of Life for Veterans With Multiple Myeloma

Watch this on-demand Webcast capturing a live CCO Webinar featuring Shaji Kumar, MD, discussing advances to improve clinical outcomes and quality of life for veterans with multiple myeloma.

Released: November 20, 2020

Expiration: November 19, 2021

No longer available for credit.

Share

Faculty

Sarah A. Holstein

Sarah A. Holstein, MD, PhD

Professor of Medicine
Division of Oncology and Hematology
University of Nebraska Medical Center
Omaha, Nebraska

Jonathan L. Kaufman

Jonathan L. Kaufman, MD

Assistant Professor
Winship Cancer Institute
Emory University
Atlanta, Georgia

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Provided by

Provided by the USF Health
ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb

GlaxoSmithKline LLC

Learning Objectives

  • Integrate timely systemic treatment for appropriate patients based on the latest multiple myeloma diagnosis and staging criteria
  • Plan individualized treatment strategies for patients with multiple myeloma through consideration of the available clinical data as well as risk assessment, comorbidities, and patient age/fitness and preferences
  • Describe the efficacy and safety evidence of novel combination therapeutic regimens for patients with multiple myeloma
  • Manage disease-related and treatment-related symptoms in patients with multiple myeloma

Program Director Disclosure

Program Director

Sarah A. Holstein, MD, PhD

Professor of Medicine
Division of Oncology and Hematology
University of Nebraska Medical Center
Omaha, Nebraska

Sarah A. Holstein, MD, PhD, has disclosed that she has received consulting fees from Celgene, Oncopeptides, and Sorrento; has received funds for research support from Oncopeptides; and has served on an advisory board or panel for GlaxoSmithKline and Genentech.

Jonathan L. Kaufman, MD

Assistant Professor
Winship Cancer Institute
Emory University
Atlanta, Georgia

Jonathan L. Kaufman, MD, has disclosed that he has received consulting fees from Janssen and Tecnofarma.

Faculty Disclosure

Primary Author

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji Kumar, MD, has disclosed that he has received consulting fees from AbbVie, Amgen, Celgene, Cellectar, GeneCentrix, Genentech, Janssen, Molecular Partners, Oncopeptides, and Takeda and funds for research support paid to his institution from AbbVie, Amgen, Bristol-Myers Squibb, CARsgen, Celgene, Janssen, Kite, MedImmune, Merck, Novartis, Roche/Genentech, Takeda, and TeneoBio.

Staff Disclosure

Staff

Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.

Jason J. Everly, PharmD

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Kristi K. Orbaugh, MSN, NP, AOCNP

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kristi Orbaugh, MSN, RNP, AOCN, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.